Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VericelVCEL -2.45%83 EV-to-OCF is 37.78 as of Jul. 19, 2026, which is 2% below its 10-year median of 38.65. GuruFocus rates VCEL with a GF Score™ of 83/100 and a GF Value™ of $55.23 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 1,412 Biotechnology companies, Vericel ranks worse than 93.56% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Vericel's Enterprise Value is $2,330.5 Mil.
Vericel's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $61.7 Mil. Therefore, Vericel's EV-to-OCF for today is 37.78.
The historical rank and industry rank for Vericel's EV-to-OCF or its related term are showing as below:
VCEL'
s EV-to-OCF Range Over the Past 10 Years
Min: -1939.96 Med: 38.65 Max: 180.8
Current: 37.78
During the past 13 years, the highest EV-to-OCF of Vericel was 180.80. The lowest was -1939.96. And the median was 38.65.
VCEL's EV-to-OCF is ranked worse than 93.56% of 1412
companies
in the Biotechnology industry
Industry Median: -3.345
vs VCEL: 37.78
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vericel's share price for today is $46.63.
Vericel's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.420.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Vericel EV-to-OCF Related Terms
Vericel EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Vericel's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vericel's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vericel EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vericel's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Vericel's EV-to-OCF falls into.
Vericel's current Enterprise Value is $2,330.5 Mil.
Vericel's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $61.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vericel (VCEL) has a EV-to-OCF of 37.78 as of Jul. 19, 2026. This is near median its historical median of 38.65. According to the industry distribution chart, Vericel ranks #1321 out of 1412 companies in the Biotechnology industry, placing it in the top 93.6%.
Is Vericel's EV-to-OCF too high?
Vericel's current EV-to-OCF of 37.78 is near median its 10-year median of 38.65. Based on the distribution chart, Vericel ranks #1321 out of 1412 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vericel has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vericel's EV-to-OCF compare to NRIX and MLYS?
According to the Biotechnology industry distribution chart, Vericel ranks #1321 out of 1412 companies for EV-to-OCF. This places Vericel in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Vericel's current EV-to-OCF is 37.78, which is near median its own 10-year median of 38.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vericel stock overvalued right now?
Based on GuruFocus' analysis, Vericel (VCEL) is currently considered Modestly Undervalued. The stock's GF Value™ is $55.23, compared to a current price of $46.63 — trading 15.6% below its estimated fair value. The current EV-to-OCF is 37.78, which is near median its 10-year median of 38.65. Vericel's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Vericel (VCEL), the current EV-to-OCF is 37.78 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vericel (VCEL) Overvalued in 2026?
Based on GuruFocus' analysis, Vericel stock appears to be undervalued.
The current stock price of $46.63 is trading 15.6% below its estimated GF Value™ of $55.23.
GuruFocus considers Vericel to be Modestly Undervalued.
Key valuation signals for VCEL:
EV-to-OCF: 37.78 (near median its 10-year median of 38.65)
GF Value™: $55.23 vs. price of $46.63 (15.6% below fair value)
No single metric tells the full story. See the VCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
83GF Score
Get the complete analysis for VCEL
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VCEL has been successfully added to your 
